University of Padua-ko ikertzaileekin lankidetzan egindako argitalpenak (27)

2024

  1. Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART

    Frontiers in Immunology, Vol. 15

  2. Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission

    Nature Medicine

2023

  1. Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile

    Pediatric Research, Vol. 94, Núm. 5, pp. 1667-1674

  2. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727

  3. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

    eClinicalMedicine, Vol. 60

2022

  1. Children living with HIV in Europe: do migrants have worse treatment outcomes?

    HIV Medicine, Vol. 23, Núm. 2, pp. 186-196

  2. Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children

    Frontiers in Immunology, Vol. 13

  3. Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy

    Frontiers in immunology, Vol. 13, pp. 860418

  4. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 5, pp. e341-e352

  5. Machine learning outperformed logistic regression classification even with limit sample size: A model to predict pediatric HIV mortality and clinical progression to AIDS

    PloS one, Vol. 17, Núm. 10, pp. e0276116

  6. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648

  7. Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence

    BMC public health, Vol. 22, Núm. 1, pp. 1312

2021

  1. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

    New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543

  2. Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort)

    Journal of the International AIDS Society, Vol. 24, Núm. 7

  3. Faster Initial Viral Decay in Female Children Living with HIV

    Journal of the Pediatric Infectious Diseases Society, Vol. 10, Núm. 5, pp. 674-676

  4. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

    BMC infectious diseases, Vol. 21, Núm. 1, pp. 5

  5. Size of HIV-1 reservoir is associated with telomere shortening and immunosenescence in early-treated European children with perinatally acquired HIV-1

    Journal of the International AIDS Society, Vol. 24, Núm. 11

  6. T cell immune discriminants of HIV reservoir size in a pediatric cohort of perinatally infected individuals

    PLoS Pathogens, Vol. 17, Núm. 4

  7. The CARMA Study: Early Infant Antiretroviral Therapy - Timing Impacts on Total HIV-1 DNA Quantitation 12 Years Later

    Journal of the Pediatric Infectious Diseases Society, Vol. 10, Núm. 3, pp. 295-301

2020

  1. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

    The Lancet HIV, Vol. 7, Núm. 8, pp. e533-e544